The 18,236 Shares of Hologic Inc. (HOLX) Stock are sold by Elaine Ullian

The 18,236 Shares of Hologic Inc. (HOLX) Stock are sold by Elaine Ullian

Hologic Inc. (NASDAQ:HOLX) Director Elaine Ullian sold 18,236 shares of the business’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $39.88, for a total transaction of $727,251.68. Following the transaction, the director now owns 42,898 shares in the company, valued at $1,710,772.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Hologic Inc. (NASDAQ:HOLX) opened at 38.32 on Friday. The company’s 50-day moving average is $38.49 and its 200 day moving average is $36.33. Hologic Inc. has a 52 week low of $31.84 and a 52 week high of $41.66. The stock has a market capitalization of $10.63 billion, a P/E ratio of 42.25 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.03. The business earned $717.40 million during the quarter, compared to the consensus estimate of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 earnings per share. On average, equities analysts forecast that Hologic Inc. will post $1.94 EPS for the current fiscal year.

Several equities analysts have weighed in on HOLX shares. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Thursday, July 28th. Leerink Swann reiterated an “outperform” rating and issued a $46.00 target price on shares of Hologic in a report on Monday, October 3rd. Zacks Investment Research lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, August 5th. Evercore ISI upgraded shares of Hologic from a “hold” rating to a “buy” rating and boosted their target price for the company from $38.00 to $42.00 in a report on Thursday, July 28th. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $42.00 target price on shares of Hologic in a report on Sunday, July 31st. Six analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $42.71.

Several large investors have recently modified their holdings of HOLX. Thompson Siegel & Walmsley LLC increased its stake in shares of Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock worth $144,000 after buying an additional 51 shares during the period. Norinchukin Bank The increased its stake in shares of Hologic by 0.4% in the second quarter. Norinchukin Bank The now owns 12,724 shares of the company’s stock worth $440,000 after buying an additional 53 shares during the period. US Bancorp DE increased its stake in shares of Hologic by 0.7% in the second quarter. US Bancorp DE now owns 13,542 shares of the company’s stock worth $468,000 after buying an additional 92 shares during the period. Calvert Investment Management Inc. increased its stake in shares of Hologic by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 15,244 shares of the company’s stock worth $527,000 after buying an additional 122 shares during the period. Finally, Raymond James Trust N.A. increased its stake in shares of Hologic by 1.1% in the second quarter. Raymond James Trust N.A. now owns 21,989 shares of the company’s stock worth $761,000 after buying an additional 231 shares during the period. Institutional investors and hedge funds own 94.51% of the company’s stock.

Hologic Company Profile

Related posts

Leave a Comment